Charles Schwab’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-426,549
| Closed | -$4.78M | – | 3093 |
|
|
2017
Q3 | $4.78M | Sell |
426,549
-4,003
| -0.9% | -$44.2K | ﹤0.01% | 1896 |
|
|
2017
Q2 | $4.74M | Sell |
430,552
-63,900
| -13% | -$639K | ﹤0.01% | 1849 |
|
|
2017
Q1 | $4.85M | Sell |
494,452
-3,255
| -0.7% | -$32.5K | ﹤0.01% | 1780 |
|
|
2016
Q4 | $5.38M | Buy |
497,707
+10,887
| +2% | +$109K | 0.01% | 1696 |
|
|
2016
Q3 | $4.99M | Buy |
486,820
+9,186
| +2% | +$100K | 0.01% | 1657 |
|
|
2016
Q2 | $6.24M | Buy |
477,634
+13,245
| +3% | +$174K | 0.01% | 1417 |
|
|
2016
Q1 | $5.11M | Sell |
464,389
-46,961
| -9% | -$418K | 0.01% | 1502 |
|
|
2015
Q4 | $4.71M | Sell |
511,350
-23,881
| -4% | -$200K | 0.01% | 1561 |
|
|
2015
Q3 | $3.71M | Buy |
535,231
+40,791
| +8% | +$349K | 0.01% | 1661 |
|
|
2015
Q2 | $4.86M | Buy |
494,440
+61,107
| +14% | +$557K | 0.01% | 1557 |
|
|
2015
Q1 | $3.84M | Buy |
433,333
+72,064
| +20% | +$574K | 0.01% | 1689 |
|
|
2014
Q4 | $3.17M | Buy |
361,269
+161,480
| +81% | +$1.31M | ﹤0.01% | 1744 |
|
|
2014
Q3 | $1.38M | Buy |
199,789
+83,454
| +72% | +$500K | ﹤0.01% | 2160 |
|
|
2014
Q2 | $612K | Sell |
116,335
-800
| -0.7% | -$3.89K | ﹤0.01% | 2540 |
|
|
2014
Q1 | $533K | Buy |
117,135
+3,000
| +3% | +$14.5K | ﹤0.01% | 2564 |
|
|
2013
Q4 | $576K | Buy |
114,135
+3,600
| +3% | +$17.3K | ﹤0.01% | 2542 |
|
|
2013
Q3 | $563K | Sell |
110,535
-1,583
| -1% | -$8.81K | ﹤0.01% | 2505 |
|
|
2013
Q2 | $595K | Buy |
+112,118
| New | +$534K | ﹤0.01% | 2440 |
|
Charles Schwab's SCLN Position: Q4 2017 in Review
Charles Schwab sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 426,549 shares — an estimated $4.78M sold.
Charles Schwab first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $6.24M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Charles Schwab reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Charles Schwab sold 426,549 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $4.78M.
- Charles Schwab first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Charles Schwab's Sciclone Pharmaceuticals Inc position peaked at $6.24M in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Charles Schwab's 13F filing for Q4 2017, filed 17 Jan 2018.